ClinicalTrials.gg
RecruitingNCT06643039NOSOVIRUSUpdated Oct 1, 2026

Nosocomial Respiratory Virus Infection

An interventional study of Nasopharyngeal swab and Questionnaire in Nosocomial Infections, sponsored by Hospices Civils de Lyon. Recruiting at 6 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 1, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Cross Infection with a site in France — 8 open to participants now, 9 under way, 1 of them phase 3. Cross Infection · France.

Planned enrollment
5th of 23
1,000 · median 244
Started
2024
with 2 others
No phase
14 of 47
3 open now
Registered
43rd of 47
by date
Lead sponsor
4 of 47
Hospices Civils de Lyon

Among the 47 studies in Cross Infection with a site in France, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 14 with no phase, and was the 43rd registered.

Cross Infection

287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.

Browse Cross Infection studies →

Open to participants now

8 of the 47 studies in Cross Infection with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 27 Cross Infection studies recruiting now, 23 (85%) set no upper age limit and 2 (7%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Cross Infection with a site in France, or all of them as a file.
02

Study summary

Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing mask. However, vaccination remains the major preventive measure.

To date, data at French national level are insufficient to describe the epidemiology of these infections, including their burden, and the potential protection of patients if vaccination coverage of health care professionals/patients is satisfactory. In addition, better understanding of the clinical characteristics of HAVRI will make it possible to identify potential sources of transmission as soon as possible and to implement appropriate hygiene measures.

We will set up a hospital-based prospective multicenter study in Bordeaux, Paris-Bichat, Dijon and Lyon, involving four inclusion services (geriatrics, internal medicine and transplantation) per hospital.

The main objective of this study is to calculate the incidence rate of hospital-acquired infections for three respiratory viruses; influenza, SARS-CoV-2 and syncytial respiratory virus (SRV), referred to as HARVI, in participating services.

Volunteered health care professionals or hospitalized patients presenting with influenza-like illness (ILI) at admission or during their stay in the participating centers will be eligible to be enrolled during the two inclusion periods: (mid-October 2024 to mid-April 2025 and mid-October 2025 to mid-April 2026).

For each patient/health care professional, a nasopharyngeal swab will be collected. A questionnaire including demographic data, medical history, vaccination, and clinical and biological data of the viral episode will also be completed by the study team. Patients tested positive for one of the viruses studied will be considered "cases" and patients tested negative as "controls".

The collected data will be pseudonymized before statistical analyses. Statistical analyses will consist of calculating incidence rates, attack rates overall and by causative virus and analysis of factors associated with the occurrence of HARVI.

The prospective design of the study will optimize the quality of the collected data (ex. consolidate the documentation of both the clinical picture and vaccination in patients and health care professionals by reducing memory bias) and allow to calculate the incidence rates, the crude and adjusted relative risks of HARVI according to the studied factors, and to describe multiple outcomes (hospitalization in intensive care units, death, etc.) based on the causative virus.

The results of this research project will allow to:

  • obtain epidemiological indicators associated with HARVI;
  • estimate the impact of HARVI on the prognosis of patients in hospital;
  • assess the impact of HARVI on the total length of hospital stay;
  • identify risk factors associated with HARVI;
  • use the results as an argument for vaccination in order to increase vaccination coverage of healthcare workers.
03

Conditions studied

  • Nosocomial Infections

Keywords

  • Hospital-acquired infection
  • COVID-19
  • Influenza
  • SRV
  • France
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults> 18 years old
  • Hospitalized patient or health care professionals presenting an ILI on admission or during the stay, meeting the following definition: fever greater than 37.8° C in the absence of taking antipyretics and/or cough or pharyngeal pain.
  • Signed consent form

Exclusion criteria

Exclusion Criteria:

  • Pregnant, parturient or breastfeeding women
  • individuals deprived of their liberty by a judicial or administrative decision
  • Individuals subject to psychiatric care
  • Individuals admitted to a health or social establishment for purposes other than research
  • Individuals under a legal protection measure (guardianship, curatorship)
  • Individuals not affiliated to a social security insurance
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Other
    Patients hospitalized in participating services for more than 24h

    Patients hospitalized for more than 24 hours in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) on admission or during hospital stay are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF.

    Biological: Nasopharyngeal swab · Other: Questionnaire

  • Other
    Volunteered health care professionals

    Volunteered health care professionals in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF

    Biological: Nasopharyngeal swab · Other: Questionnaire

Interventions

  • BiologicalNasopharyngeal swab

    Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.

  • OtherQuestionnaire

    questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.

06

What researchers measure

Primary outcomes

  1. Incidence of hospital-acquired respiratory viral infections

    The primary endpoint will be evaluated by calculating the incidence of hospital-acquired respiratory viral infections overall and by type of virus (influenza, COVID-19, RSV) during the surveillance period. incidence rate will be estimated by the ration of number of incident cases over the study period to the cumulative observation time (in person-weeks) of hospitalized patients. Incidence density will be estimated by the ratio of number of incident cases during successive weekly observation periods to the cumulative observation times calculated over the same periods.

    Time frame: At inclusion

07

Study locations

1 of 6 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

Of 59 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 31 months is above that.

Counting every sponsor, half of 61 studies reached it within 16 months; a quarter within 7 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jul 2026 → Jul 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 15, 2024
StartActual
Dec 5, 2024
Primary completionEst.
Jul 5, 2027was Jul 2026
CompletionEst.
Jul 5, 2027was Jul 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 France)
  • Saint Louis Hospital · Paris, France
  • Saint Louis Hospital · Paris, France
Oct 1, 2026
Primary completion
Jul 5, 2026→Jul 5, 2027
Oct 1, 2026
Study completion
Jul 5, 2026→Jul 5, 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    2 sites added
    Show 2 added (2 France)
    • Saint Louis Hospital · Paris, France
    • Saint Louis Hospital · Paris, France
    Primary completion Jul 5, 2026→Jul 5, 2027
    Study completion Jul 5, 2026→Jul 5, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06643039
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Dec 5, 2024
Primary completion
Jul 5, 2027 (estimated)
Completion
Jul 5, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Philippe VANHEMS, MD, PhD
Contact
Philippe.vanhems@chu-lyon.fr
+33 4 72 11 07 20
Mitra SAADATIAN-ELAHI
Contact
Mitra.elahi@chu-lyon.fr
+33 4 72 11 07 18

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion